SHShazia Hussain

Shazia Hussain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shazia Hussain has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fasting with adrenal insufficiency: Practical guidance for healthcare professionals managing patients on steroids during Ramadan

    by Sufyan Hussain, Shazia Hussain, Ruzwan Mohammed, Karim Meeran, Nazim Ghouri

    There are limited recommendations for fasting in many chronic diseases such as adrenal insufficiency (AI). Research in such situations highlights potential for complications and need for education for patients with AI undertaking fasting during Ramadan. This article aims to provide up‐to‐date guidance for healthcare professionals to educate, discuss and manage patients with AI who are considering fasting in Ramadan and is religiously compatible. Latest guidance on this topic and the evidence base for steroid dosing are reviewed and discussed. Risk stratification for patients with AI and optimal strategies for management, including steroid dosing, are detailed. Our review highlights that patients with AI wishing to fast should undergo a thorough risk assessment ideally several months before Ramadan. ‘High risk’ and ‘Very high risk’ patients should be encouraged to explore alternative options to fasting discussed below. Prior to the commencement of Ramadan, all patients must receive up‐to‐date education on sick day rules, instructions on when to terminate their fast or abstain from fasting, carry steroid warning information and must have a valid intramuscular (IM) hydrocortisone pack and know how to administer this. Switching patients with AI desiring to fast from multiple daily hydrocortisone replacement to prednisolone 5 mg once daily at dawn (during Suhoor or Sehri) is recommended and discussed. Patients on fludrocortisone for AI should be advised to take their total dose at dawn. We provide practically relevant case‐based scenarios to help with the application of this guidance. Future efforts need to focus on healthcare professional awareness and further research in this setting.


  • Honesty is always best

    by Shazia Hussain, Helen Storr, William Drake

    A three year old boy was referred for surgical correction of an undescended right testis. Intra-operatively he was found to have a hyperplastic right gonad which was in continuation with a unilateral fallopian tube, prompting analysis of his karyotype. This showed 46XX/XY mosaicism with 88% of the cells being XX and 12% XY. The post-operative histology confirmed mixed testicular and ovarian tissue in the right gonad. He appeared phenotypically male and had blaschko lines consistent with the diagnosis of genetic mosaicism. Although a HCG stimulation test showed some testicular function in his left gonad, this was insufficient to allow normal progression through puberty. He commenced regular Sustanon injections aged 12 years with good effect. Over the next few years, his left testicular volume gradually increased to 8–10 mls, after which there was no further enlargement raising the possibility of a dysgenetic testis. Ultrasound imaging showed a single small left testis with slight heterogeneity but no malignant features. At the completion of puberty, he reported no symptoms suggestive of erectile dysfunction, had a muscular physique and was referred for a right testicular implant. Sustanon was discontinued and since then his serum AFP, HCG and testosterone levels have remained within the normal ranges. He is currently 25 years old and married. On clinical examination, the left gonad remains soft, in keeping with a degree of germ cell failure, but there are no palpable worrying features. Recent semen analysis shows persistent severe oligospermia. He remains off testosterone replacement (serum testosterone level 18 nmol/l) with the aim to freeze his sperm, as soon as the levels are sufficient to allow this, for potential intracytoplasmic sperm injection, should he wish to pursue this. This case describes a rare cause of hypogonadism. It emphasises the role and treatment aims of testosterone replacement in young hypogonadal males, the impact this can have on spermatogenesis and the complex fertility issues that may arise in adulthood.

  • A rare cause of elevated testosterone levels in an adult female

    by Shazia Hussain, Anju Sahdev, William Drake

    A 49 year old Russian lady was found to have an elevated testosterone level (9 nmol/l) when investigated for hair loss. This was first detected some years ago when she apparently was given a provisional diagnosis of polycystic ovarian syndrome. When assessed in her local endocrine unit she did not report any excessive body hair growth or symptoms of virilisation. She claimed to reach the menopause aged 45 years and reported a family history of early menopause. Initial blood tests confirmed normal adrenal androgens and sex hormone binding globulin. A plan for extensive endocrine work-up and pelvic imaging was recommended, however, the patient subsequently requested a referral to our unit for a second opinion. Here she gave a significantly different history. She reported primary amenorrhoea which had previously been investigated in Russia. Although not available for review at the time of consultation, pelvic imaging there had shown an absent uterus and possible gonadal tissue in both inguinal canals. Clinically she appeared phenotypically female with no signs of virilisation. This in combination with an absent uterus and serum testosterone levels within the male reference range would be consistent with a potential diagnosis of androgen insensitivity syndrome. This was confirmed on karyotype, which returned as 46XY. A MRI pelvis showed a normal vaginal vault but there was no cervix or uterus seen. Surprisingly, the patient was also found to have mixed ovarian and testicular tissue. Due to the risk of future malignant transformation she has been referred for a gonadectomy. Pre-operative germ cell tumour markers (AFP and HCG) have returned as mildly elevated (13.9 and 4 unit/l, respectively), although Ca-125 is within the reference range. She awaits whole body cross-sectional imaging to ensure there are no distant sinister findings or associated urological abnormalities before proceeding with surgery. This case highlights the need for careful assessment of patients with elevated androgens; some of the sensitivities that accompany the assessment of reproductive disorders; the importance of considering androgen insensitivity syndrome in adult patients as a potential differential diagnosis; and the fact that, after her gonadectomy, oestrogen replacement in this patient can be unopposed in the absence of a uterus.

  • Lymphocytic hypophysitis in a pregnant patient with type 1 diabetes

    by Shazia Hussain, Huda Mohammed Shahriar, William Drake

    A 34-year old female with type 1 diabetes presented to the antenatal clinic complaining of polydipsia, polyuria and nocturia. She was 12 weeks pregnant with adequate glycaemic control on a basal-bolus insulin regime. She reported new onset headaches but no deterioration in vision. On examination, her visual fields were full to confrontation with red pin. She was eunatraemic (Na 138 mmol/l), had an early morning cortisol of 332 nmol/l and normal thyroid function tests (FT4 16 pmol/l, TSH 1.73 munit/l). A formal water deprivation test was not undertaken due to the potential risk of significant dehydration to the pregnant mother. She was, therefore, commenced on oral Desmopressin for suspected diabetes insipidus, advised to drink to thirst and referred for a non-contrast pituitary MRI to exclude a mass lesion. This showed a slightly bulky pituitary gland with a visible posterior bright spot. Although her osmotic symptoms improved after starting Desmopressin, she was becoming disproportionately fatigued to the stage of pregnancy, necessitating a small dose of Hydrocortisone, with good symptomatic benefit. A provisional diagnosis of lymphocytic hypophysitis was made. Regular scans confirmed good fetal growth throughout the pregnancy and she subsequently delivered a healthy baby boy at term. Her pituitary function was reassessed post-partum. A pre-hydrocortisone cortisol level was satisfactory at 439 nmol/l and she reported no polydipsia or polyuria after omission of her Desmopressin. A repeat MRI pituitary showed a reduction in the size of the gland and basal pituitary function returned to normal, consistent with resolution of the hypophysitis. She was discharged from clinic on her pre-pregnancy doses of insulin and off all pituitary hormone replacement. She has recently, however, represented in the first trimester of her second pregnancy with polyuria and polydipsia and is currently undergoing assessment by her local endocrine team. Lymphocytic hypophysitis is well reported to occur in pregnant women, particularly when there is a history of autoimmunity, and may well be transient. Diabetes insipidus in pregnancy is associated with diagnostic challenges especially as standard dynamic pituitary function tests are unsafe. The diagnosis is, therefore, often presumptive and this case highlights the importance of close monitoring during pregnancy and early assessment of the pituitary axis post-partum.


  • A challenging case of progressive follicular thyroid cancer

    by Shazia Hussain, Carmel Brennan, Nick Plowman, Kate Newbold, William Drake

    A 60 year old gentleman with a history of renal stones presented 5 years ago with left sided flank pain. A CT of his renal tract showed an unexpected metastatic deposit in the left iliac crest. Cross-sectional whole body imaging, performed to locate the primary, also identified an expansile soft tissue mass in the T8 vertebral body and a predominantly cystic looking left sided thyroid nodule. He proceeded to have an iliac crest biopsy which was consistent with metastatic follicular thyroid cancer. A dedicated thyroid ultrasound scan showed a malignant looking thyroid nodule with no suspicious lymphadenopathy. He was referred for an urgent thyroidectomy. Post-operative histology was reported as widely invasive follicular thyroid cancer with evidence of vascular invasion and tumour necrosis. He was commenced on suppressive doses of Levothyroxine and was referred to our centre for radioiodine. A repeat look at his pre-operative spinal imaging was worrying for impending spinal cord compression from the T8 metastatic deposit. He, therefore, received urgent radiotherapy to this lesion and to the left ilium. After completing the radiotherapy he received radioiodine ablation. Post-ablation I-131 scan showed iodine avidity in the thyroid bed, T8 and the left ilium. Over the next two years he received four therapy doses of radioiodine with good concentration in the metastatic deposits. His stimulated thyroglobulin fell from 6,840 μg/l to 3,544 μg/l. However, in May 2016, four months after his last radioiodine therapy dose, he reported worsening bone pain. His unstimulated thyroglobulin rose to >5,000 μg/l and a repeat MRI scan showed new acetabular deposits and a left pubic ramus pathological fracture necessitating more radiotherapy to this site. A repeat look at his post-therapy scans confirmed these sites as being non-iodine avid. In view of this, a PET scan was arranged to look for other non-iodine avid sites. Unfortunately, this identified multiple spinal and lung metastases. He was given bisphosphonate therapy and his case was brought back to the thyroid multi-disciplinary team meeting where funding for Sorafenib was discussed. However, the patient had done some of his own research and was keen to enrol in a clinical trial that specifically looked at treatment options which may restore iodine avidity to his advancing disease first. Differentiated thyroid cancers are usually responsive to radioiodine therapy. Refractory follicular thyroid cancers are rare and treatment options are limited. This case highlights the role of the multi-disciplinary team in managing these complex patients.

  • Open Access

    Ketosis-prone diabetes and SLE co-presenting in an African lady with previous gestational diabetes

    by S Hussain, S Keat, S V Gelding

    Summary: We describe the case of an African woman who was diagnosed with ketosis-prone diabetes with diabetes-associated autoantibodies, after being admitted for diabetic ketoacidosis (DKA) precipitated by her first presentation of systemic lupus erythematosus (SLE). She had a seven-year history of recurrent gestational diabetes (GDM) not requiring insulin therapy, with return to normoglycaemia after each pregnancy. This might have suggested that she had now developed type 2 diabetes (T2D). However, the diagnosis of SLE prompted testing for an autoimmune aetiology for the diabetes, and she was found to have a very high titre of GAD antibodies. Typical type 1 diabetes (T1D) was thought unlikely due to the long preceding history of GDM. Latent autoimmune diabetes of adults (LADA) was considered, but ruled out as she required insulin therapy from diagnosis. The challenge of identifying the type of diabetes when clinical features overlap the various diabetes categories is discussed. This is the first report of autoimmune ketosis-prone diabetes (KPD) presenting with new onset of SLE. Learning points: DKA may be the first presentation of a multi-system condition and a precipitating cause should always be sought, particularly in women with a history of GDM or suspected T2D. All women with GDM should undergo repeat glucose tolerance testing postpartum to exclude frank diabetes, even when post-delivery capillary blood glucose (CBG) tests are normal. They should also be advised to continue CBG monitoring during acute illness in case of new onset diabetes. KPD comprises a spectrum of diabetes syndromes that present with DKA, but subsequently have a variable course depending on the presence or absence of beta cell failure and/or diabetes autoantibodies. KPD should be considered in a patient with presumed T2D presenting with DKA, especially if there is a personal or family history of autoimmune diabetes. LADA should be suspected in adults presumed to have T2D, who do not require insulin therapy for at least six months after diagnosis and have anti-GAD antibodies. Patients with autoimmune diabetes have an increased risk of other autoimmune diseases and screening for thyroid, parietal cell, coeliac and antinuclear antibodies should be considered.


  • Intravascular large B‐cell lymphoma presenting as a pituitary mass with bilateral adrenal enlargement and haemophagocytic lymphohistiocytosis

    by Shazia Hussain, Simon Hallam, Luis Beltran, Athar Haroon, Kalpita Majumdar, Jonathan Shamash, Rasheeta Sivapackianathan, William Drake


  • Open Access

    Pure aldosterone-secreting adrenocortical carcinoma in a patient with refractory primary hyperaldosteronism

    by S Hussain, E Panteliou, D M Berney, R Carpenter, M Matson, A Sahdev, M Bell, E O'SUllivan, W M Drake

    Summary: We describe a young male patient with longstanding hypertension, who was diagnosed with primary hyperaldosteronism and treated by an attempted retroperitoneoscopic total unilateral adrenalectomy for a left-sided presumed aldosterone-secreting adenoma. Imaging had shown an unremarkable focal adrenal lesion with normal contralateral adrenal morphology, and histology of the resected specimen showed no adverse features. Post-operatively, his blood pressure and serum aldosterone levels fell to the normal range, but 9 months later, his hypertension recurred, primary aldosteronism was again confirmed and he was referred to our centre. Repeat imaging demonstrated an irregular left-sided adrenal lesion with normal contralateral gland appearances. Adrenal venous sampling was performed, which supported unilateral (left-sided) aldosterone hypersecretion. Redo surgery via a laparoscopically assisted transperitoneal approach was performed and multiple nodules were noted extending into the retroperitoneum. It was thought unlikely that complete resection had been achieved. His blood pressure returned to normal post-operatively, although hypokalaemia persisted. Histological examination, from this second operation, showed features of an adrenocortical carcinoma (ACC; including increased mitoses and invasion of fat) that was assessed as malignant using the scoring systems of Weiss and Aubert. Biochemical hyperaldosteronism persisted post-operatively, and detailed urine steroid profiling showed no evidence of adrenal steroid precursors or other mineralocorticoid production. He received flank radiotherapy to the left adrenal bed and continues to receive adjunctive mitotane therapy for a diagnosis of a pure aldosterone-secreting ACC. Learning points: Pure aldosterone-secreting ACCs are exceptionally uncommon, but should be considered in the differential diagnosis of patients presenting with primary aldosteronism. Aldosterone-producing ACCs may not necessarily show typical radiological features consistent with malignancy. Patients who undergo surgical treatment for primary aldosteronism should have follow-up measurements of blood pressure to monitor for disease recurrence, even if post-operative normotension is thought to indicate a surgical ‘cure’. Owing to the rarity of such conditions, a greater understanding of their natural history is likely to come from wider cooperation with, and contribution to, large multi-centre outcomes databases.


  • Peri-operative [a]-blockade: efficacy of intravenous phenoxybenzamine vs oral phenoxybenzamine in patients with phaeochromocytoma and paraganglioma

    by Shazia Hussain, Kirun Gunganah, Michael Ashby, Robert Carpenter, Mona Waterhouse, Maralyn Druce, William Drake, Scott Akker

    Introduction: Regimens for pre-operative α and β-blockade for patients with secretory phaeochromocytomas/paragangliomas vary widely between centres. The worldwide lack of availability of intravenous phenoxybenzamine (Goldshield) has removed a useful tool in the management of phaeochromocytoma crisis and has necessitated a change in our institution’s routine pre-operative strategy. We compare pre, peri and post-operative surrogate measures of blockade in a cohort of patients receiving iv phenoxybenzamine with an oral regimen. Methods: Of 41 patients with phaeochromocytoma/paraganglioma seen between 2009 and 2012, 19 patients were included in this retrospective audit. Patients were only included if the same surgeon (RAC) and anaesthetist (MA) were present and were excluded if a transfusion was required. All patients had α blockade with oral phenoxybenzamine for at least 3 weeks prior to surgery. In the immediate 3-day pre-operative period five patients had accelerated oral phenoxybenzamine therapy ± intravenous fluids and 14 patients had intravenous phenoxybenzamine ± intravenous fluid. We assessed intraoperative parameters of α blockade efficacy including requirement for sodium nitroprusside (SNP) and intravenous fluids. We assessed postoperative fluid requirement, use of and response to adrenaline, blood pressure and heart rate variability. Results: Patients treated with intravenous phenoxybenzamine pre-operatively required less SNP (6.4 vs 12.3 mg) and less intra-operative intravenous fluids (2.9 l vs 5.2 l) compared to patients treated with oral phenoxybenzamine. Mean systolic BP in the 3-day pre-operative period was lower in the i.v. group (123 vs 130 mmHg) and the immediate post-operative systolic BP was higher in the iv group (108 mmHg vs 93 mmHg). Data including tumour type and size, catecholamine/metanephrine levels, postural BPs, and dose of α and β-blockade will be presented. Conclusion: Although a small cohort, the data suggest that patients treated with iv phenoxybenzamine have better pre-operative BP control, require less intraoperative intervention and have less post-operative hypotension than patients treated with oral phenoxybenzamine. We invite other centres to report their experience.